Showing 26–33 of 33 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
David S.C. Hui, Chi Chiu Leung
…tions (RTI), such as community-acquired pneumonia (CAP) and tuberculosis (TB), are important causes of morbidity and mortality. The ongoing outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and epidemic waves of avian influenza A(H7N9) since their eme…
Inna Friesen, Timo Ulrichs, L. A. Hryshchuk, H. S. Saturska
… to compare the epidemiological situation of chemoresistant tuberculosis in Germany and Ukraine, in addition analyzing the nature and features of chemoresistant tuberculosis in 192 patients treated at the Ternopil Regional TB Dispensary Ukraine during 2017—2018.
 Materials a…
Olena Ivanova, Dragoș Băiceanu, Abhishek Bakuli, M. Vogel, Cristina Popa, et al.
…tidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients are likely to suffer from TB-related morbidity, social and economic consequences during and beyond anti-TB treatment. The aim of this study is to describe clinical and socio-economic outcomes o…
Sharenja Ratnakumar, Xin Yi Choon, Moerida Belton, Paramita Palchaudhuri, Louise Cotton
… Although Europe represents only 3% of the global burden of tuberculosis (TB), globally it has one of the highest proportions of multidrug-resistant TB (MDRTB). TB infection in Eastern Europe remains one of the key drivers of this epidemic. We investigated the Eastern European/Ba…
Harichander S, Bangalee V, Oosthuizen F
…ulnerable demographic in the context of drug-resistant (DR) tuberculosis (TB) due to their increased likelihood of close contact with adults diagnosed with the disease. Approximately 25 000-30 000 children develop DR-TB annually. While treatment success rates for DR-TB in childre…
Pratibha Singhal, Prajay Lunia, Kapil Salgia, Iram Syed
…er drugs. Neuroimaging in such cases can help in confirming diagnosis of cycloserine neurotoxicity & guide necessary changes to treatment to prevent morbidity & mortality.
Muhammad Kashif Munir
…iety of Berlin and announced the discovery of Mycobacterium tuberculosis (M. tuberculosis). That moment marked the turning point when a mysterious, hindering illness was finally recognized and defined as a specific infectious disease and laid the scientific foundation for diagnos…
Francesca M Conradie
BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) an…